Jasper Therapeutics posts Q1 net loss as briquilimab program advances

Jasper Therapeutics

14/05/2026 21:26

Overview

US biotechnology firm's fiscal Q1 net loss totaled $1.2 mln, EPS loss was $0.04

Company advanced briquilimab clinical program, refiled Phase 2b protocol with FDA

Jeet Mahal appointed CEO to lead next phase of clinical growth

Outlook

Jasper plans to begin Phase 2b study of briquilimab in CSU in H2 2026, pending funding

Company is seeking additional funding to start the planned Phase 2b study in CSU

Jasper has refiled updated Phase 2b protocol with FDA for briquilimab in CSU

Result Drivers

CLINICAL DEVELOPMENT COSTS - R&D expenses driven by advancement of briquilimab program and analysis of clinical data in CSU

REGULATORY PREPARATIONS - Refiling of updated Phase 2b protocol with FDA as part of preparations for next clinical trial phase

Company press release: ID:nGNXbhs1Cc

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.04
Q1 Net Income
-$1.2 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Jasper Therapeutics Inc is $6.50, about 606.4% above its May 13 closing price of $0.92

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)